Loading
Loading
Research Overview
Essential coenzyme in redox metabolism; serves as a substrate for sirtuins (SIRT1–7), PARP enzymes, and CD38, all of which regulate energy homeostasis, DNA repair, and cellular stress responses. NAD+ levels decline ~50% between 40–60 years of age.
NAD+ is a dinucleotide coenzyme that serves as an electron acceptor in glycolysis and the TCA cycle, cycling between oxidised (NAD+) and reduced (NADH) forms to transfer electrons to the mitochondrial electron transport chain. Beyond its role as an electron carrier, NAD+ is consumed as a substrate by three major enzyme families: sirtuins (NAD+-dependent deacylases implicated in metabolic gene regulation and ageing), PARPs (poly ADP-ribose polymerases involved in DNA repair), and CD38 (a cyclic ADP-ribose hydrolase involved in calcium signalling). Preclinical research has studied how NAD+ availability influences these enzyme activities and their downstream biological consequences.
A major focus of NAD+ preclinical research has been the relationship between declining NAD+ levels and ageing biology. Animal model studies have documented decreased tissue NAD+ concentrations with advancing age across multiple tissues, and have used supplementation and biosynthetic pathway modulation to examine whether restoring NAD+ levels influences ageing-associated phenotypes in laboratory model systems.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, nad+ (nicotinamide adenine dinucleotide) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
NAD+ (Nicotinamide Adenine Dinucleotide) research is most relevant to protocols examining:
Cellular energy metabolism and sirtuin activation research
DNA repair and PARP enzyme biology studies
Age-related NAD+ decline and longevity investigations
Metabolic health and insulin sensitivity improvement research
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Primary outcomes are typically strongest in this window. Human trial literature provides benchmarks for comparison.
Washout & review
Allow full washout (~5× half-life: ~Hours (rapid cellular uptake)). Review data, confirm baseline recovery before any repeat protocol.
Essential coenzyme in redox metabolism; serves as a substrate for sirtuins (SIRT1–7), PARP enzymes, and CD38, all of which regulate energy homeostasis, DNA repair, and cellular stress responses. NAD+ levels decline ~50% between 40–60 years of age.
| Parameter | Value |
|---|---|
| Dose range | 500–1000 mg/day (oral NMN/NR) |
| Alt. dose 2 | 100–500 mg IV/sub-q (NAD+ direct) |
| Schedule | Daily |
| Route | Subcutaneous, Intravenous, Oral (precursors) |
| Half-life | ~Hours (rapid cellular uptake) |
Available from Capital Peptides
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.
